CMS opened a formal review to consider a national Medicare coverage policy for Boston Scientific's Watchman left atrial appendage closure device to prevent stroke May 21.
Watchman was approved by FDA in March after three advisory panels and two pivotal trials. The approved labeling for reducing the risk of thromboembolism from the left atrial appendage in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?